Julius Asubonteng

Regeneron Pharmaceuticals, Inc.

Poster(s):

• (SLC-038) Diagnosis Patterns of Retinal Vasculitis in Real-World Data
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (C-153) Mind the Gap: a literature review to assess definitions of treatment discontinuation in oncology studies
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (B-188) Safety and Effectiveness of Cemiplimab in Combination with Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: An Ongoing Real World Evidence Study
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET